Clinical studies recruiting near Humble

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Phase 3 · EyePoint Pharmaceuticals, Inc. · NCT07449936 Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Dee
Phase 3 · Anthos Investigational site 9833 · Anthos Therapeutics, Inc. · NCT05712200 CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T
Phase 1/Phase 2 · Accurate Clinical Research, Inc · COUR Pharmaceutical Development Company, Inc. · NCT06783309 A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or
Phase 3 · Research Site · AstraZeneca · NCT07667803 Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu
Phase 3 · Texas Oncology - Gulf Coast · Pfizer · NCT07222566 Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease o
Phase 3 · Clinical Trial Site · Alnylam Pharmaceuticals · NCT07181109 A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Texas Oncology - Gulf Coast · Pfizer · NCT07144280 Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Texas Oncology - Gulf Coast · Pfizer · NCT07222800 Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Phase 2 · Memorial Hermann Northeast Hospital · Alliance for Clinical Trials in Oncology · NCT02523014 A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase 2 · Accurate Clinical Research, Inc · Eli Lilly and Company · NCT07533019 Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Phase 2 · Site 101 · Yarrow Bioscience, Inc. · NCT07682896 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Vital Heart and Vein · Amgen · NCT07037433 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Phase 3 · Accurate Clinical Research · EMD Serono Research & Development Institute, Inc. · NCT07355218 To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Phase 2 · Research Site · Stamford Pharmaceuticals, Inc. · NCT06344052 A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Co
Phase 3 · Research Site · AstraZeneca · NCT06742723 AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous
NA · Vital Heart and Vein · Boston Scientific Corporation · NCT06959524 Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NA · Accurate Clinical Research, Inc. · Philip Morris Products S.A. · NCT07108166 WRAP North America
Phase N/A · Humble Vascular Surgical Center · Merit Medical Systems, Inc. · NCT06807099 MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Humble Vascular Surgical Center · Stryker Instruments · NCT03072927 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Phase 3 · Vital Heart and Vein · Amgen · NCT07293260 A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a
Phase 3 · Research Site · AstraZeneca · NCT07000357 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Phase 3 · Vital Heart and Vein · Amgen · NCT07037459 Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Perc
Phase 4 · Vital Heart and Vein · Duke University · NCT06909565 Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Phase 3 · Baxis Site 02 · Baxis Pharmaceuticals, Inc. · NCT06911424 A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult
Phase 3 · Regeneron Pharmaceuticals · NCT06541704 Lumason® Infusion vs. Bolus Administrations
Phase 3 · Vital Heart and Vein · Bracco Diagnostics, Inc · NCT06400004 A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D
Phase 3 · Research Site · AstraZeneca · NCT06883305 Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NA · Vital Heart and Vein · Reprise Biomedical, Inc. · NCT07632001 Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
NA · Jaeb Center for Health Research · NCT05145491 A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc
Phase 3 · Provecta Research Path Forward Ventures · Boehringer Ingelheim · NCT07220083

Look up another city

Look up another condition